Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC ± Toripalimab in HR+ HER2-low Metastatic Breast Cancer
CTR20233126Phase 2Terminated
- Sponsor
- Rongchang Pharmaceuticals
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dapoxetine, toripalimab in breast cancer, sponsored by Rongchang Pharmaceuticals. Started Oct 2023; status: terminated.
02
Drugs
dapoxetinetoripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20233126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233126.